状细胞病的药理疗法的进展:目前的情况是什么?
1Inova Adult Sickle Cell Center, University of Virginia School of Medicine, Inova Fairfax Medical Campus, Fairfax, VA, USA.
两种新的基因疗法为状细胞疾病 (SCD) 提供了希望,这是最常见的遗传性血液疾病. 在不断变化的治疗环境中,对专家的访问对于综合护理至关重要.
科学领域:
- 血液学 血液学 血液学
- 遗传学 遗传学 是一个
- 药理学 药理学是指药理学的学科.
背景情况:
- 状细胞疾病 (SCD) 是最常见的遗传性血液疾病,历史上资金不足和被忽视.
- 最近的进展包括两种新的基因疗法,重点转移到SCD管理上.
- 之前有限的治疗选择加剧了患者的痛苦和早期死亡率.
研究的目的:
- 审查目前用于SCD的药物和治疗方法.
- 分析新批准的SCD基因疗法的实施过程.
- 在SCD中讨论制药发展的未来.
主要方法:
- 对现有的SCD药物和治疗方法的文献综述.
- 对新基因疗法的实施挑战进行批判性分析.
- 关于当前和未来SCD护理的专家意见.
主要成果:
- 最近批准基因疗法增加了对SCD的关注.
- 这些新型治疗方法的实施和可访问性存在重大挑战.
- 确保SCD患者获得专业护理至关重要.
结论:
- 虽然新的基因疗法代表了突破,但公平的准入和专业的护理仍然至关重要.
- 需要持续的研究和开发来解决SCD治疗的复杂性.
- 状细胞专家提供的综合护理对于改善结果至关重要.
更多相关视频
07:24A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy
05:23Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
Published on: March 14, 2017
相关概念视频
iPS Cell Differentiation
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Drug Therapy
Antianxiety Medications
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
